Monday, 23 Jul 2018

PsA/SpA

Date Typesort ascending Title Save
13 Jun 2018 Social Lindstrom studied their Swedish AS registry and found that While the presence of Uveitis was assoc w/ better TNFi responses; all other comorbidities yielded lesser TNFi responses. #EULAR2018 @RheumNow OP0023 https://t.co/bltRC4khbL
07 Oct 2016 Social Am I wrong?Otezla warnings overstate risk of depression % wt loss; yet understate diarrhea 9% & D/C for diarrhea <2% https://t.co/UwFi8b6txr
16 Oct 2017 Social Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz https://t.co/0OcGOUDg9T
15 Jun 2018 Social RT @PhilipGardiner: Are you thinking of a ‘treat to target’ approach to Psoriatic Arthritis? You’ll need the GRAPPA app (free) https://t.co…
24 Feb 2017 Social Study of >43K Pso, PsA, AS pts shows 14-34% increase risk for depression; but not for suicide or suicidal ideation. https://t.co/STsQikW5pN
09 Nov 2017 Social RT @japaoli19: @RheumNow Agree. Only 6% were strong recommendations. Glad they addressed comorbidities but management not necessarily consi…
30 Jul 2015 Social PSOLAR registry Infection risk w/ age, DM, smoking, prior Infx, INFLX, ADA. Low rate w/ Stelara 0.83 & ETN 1.47/100PY http://t.co/OxTbxe2HN9
05 Nov 2017 Social RT @japaoli19: Low dose CT detects more spinal progression vs xray in AS measured by ct syndesmophyte sc #582 #ACR17 @rheumnow https://t.…
29 Jun 2018 Social European Commission has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of adults with active psoriatic arthritis (PsA) with an inadequate response to DMARDs https://t.co/G6YYXSuUyQ
18 Apr 2017 Social Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ https://t.co/2UcTOZKhYf
20 Jan 2017 Social Small prospective study shows a potential benefit of Vedolizumab in IBD-associated SpA. 46% pts improved @drpetryna https://t.co/pgoKO8ZabS
17 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/ffsAfiaU70
29 Apr 2016 Social Extensive skin psoriasis is a risk factor for Psoriatic Arthritis - other risk factors nail dz, obesity & smoking https://t.co/NZAqi0RJDB
06 Nov 2017 Social Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts… https://t.co/O1xSQ6nafD
25 May 2017 Social Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
17 Feb 2017 Social RT @DrRachelTate: RAPID3 as a potential useful tool for PsA. Arthur Kavanaugh, MD and Eric Ruderman, MD #rwcs2017 @RWCSmtg @RheumNow https:…
27 Jun 2016 Social RAPID3 gives similar outcome info to BASDAI and ASDAS in a cross sectional study of 85 AS patients https://t.co/uIfXJpB5s3
07 Nov 2017 Social RT @DrPetryna: FUTURE5: Cosentyx clinically&radiofraph superior toPBO. mTSS non-progression 88%Cosentyx vs73% PBO #L17 #acr17 @RheumNow htt…
07 Nov 2017 Social RT @uptoTate: IBD assoc. w/ more severe SpA. Occurs w/ rate of 0.7/100 patient yrs/ 5 yrs in DESIR cohort. #ACR17 @RheumNow #2512 https://t…
23 Aug 2016 Social Structural progression is low (~5%) in early SpA; Sacroiliitis risk factors were B27, smoking & MRI SI inflammation https://t.co/MWsxlbb6lt